330000Accelerated FilerfalsefalseAmphastar Pharmaceuticals, Inc.--12-31false0001297184Q3falseYestrueDEfalse2020-09-30000001297184us-gaap:SalesReturnsAndAllowancesMember2020-01-012020-09-300001297184us-gaap:SalesReturnsAndAllowancesMember2019-01-012019-09-300001297184us-gaap:SalesReturnsAndAllowancesMember2020-09-300001297184us-gaap:SalesReturnsAndAllowancesMember2019-12-310001297184us-gaap:SalesReturnsAndAllowancesMember2019-09-300001297184us-gaap:SalesReturnsAndAllowancesMember2018-12-310001297184amph:November2014ShareRepurchasePlanMember2020-07-012020-09-300001297184amph:November2014ShareRepurchasePlanMember2020-01-012020-09-300001297184amph:November2014ShareRepurchasePlanMember2019-07-012019-09-300001297184amph:November2014ShareRepurchasePlanMember2019-01-012019-09-300001297184amph:November2014ShareRepurchasePlanMember2020-08-040001297184us-gaap:TreasuryStockMember2020-07-012020-09-300001297184us-gaap:TreasuryStockMember2020-04-012020-06-300001297184us-gaap:TreasuryStockMember2020-01-012020-03-310001297184us-gaap:TreasuryStockMember2019-07-012019-09-300001297184us-gaap:TreasuryStockMember2019-04-012019-06-300001297184us-gaap:TreasuryStockMember2019-01-012019-03-310001297184us-gaap:CommonStockMember2020-07-012020-09-300001297184us-gaap:CommonStockMember2020-04-012020-06-300001297184us-gaap:CommonStockMember2020-01-012020-03-310001297184us-gaap:CommonStockMember2019-07-012019-09-300001297184us-gaap:CommonStockMember2019-04-012019-06-300001297184us-gaap:CommonStockMember2019-01-012019-03-3100012971842020-06-3000012971842020-03-3100012971842019-06-3000012971842019-03-310001297184us-gaap:RetainedEarningsMember2020-09-300001297184us-gaap:ParentMember2020-09-300001297184us-gaap:NoncontrollingInterestMember2020-09-300001297184us-gaap:AdditionalPaidInCapitalMember2020-09-300001297184us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-300001297184us-gaap:RetainedEarningsMember2020-06-300001297184us-gaap:ParentMember2020-06-300001297184us-gaap:NoncontrollingInterestMember2020-06-300001297184us-gaap:AdditionalPaidInCapitalMember2020-06-300001297184us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-300001297184us-gaap:RetainedEarningsMember2020-03-310001297184us-gaap:ParentMember2020-03-310001297184us-gaap:NoncontrollingInterestMember2020-03-310001297184us-gaap:AdditionalPaidInCapitalMember2020-03-310001297184us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-310001297184us-gaap:RetainedEarningsMember2019-12-310001297184us-gaap:ParentMember2019-12-310001297184us-gaap:NoncontrollingInterestMember2019-12-310001297184us-gaap:AdditionalPaidInCapitalMember2019-12-310001297184us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001297184us-gaap:RetainedEarningsMember2019-09-300001297184us-gaap:ParentMember2019-09-300001297184us-gaap:NoncontrollingInterestMember2019-09-300001297184us-gaap:AdditionalPaidInCapitalMember2019-09-300001297184us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-09-300001297184us-gaap:RetainedEarningsMember2019-06-300001297184us-gaap:ParentMember2019-06-300001297184us-gaap:NoncontrollingInterestMember2019-06-300001297184us-gaap:AdditionalPaidInCapitalMember2019-06-300001297184us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-06-300001297184us-gaap:RetainedEarningsMember2019-03-310001297184us-gaap:ParentMember2019-03-310001297184us-gaap:NoncontrollingInterestMember2019-03-310001297184us-gaap:AdditionalPaidInCapitalMember2019-03-310001297184us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-03-310001297184us-gaap:RetainedEarningsMember2018-12-310001297184us-gaap:ParentMember2018-12-310001297184us-gaap:NoncontrollingInterestMember2018-12-310001297184us-gaap:AdditionalPaidInCapitalMember2018-12-310001297184us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-310001297184amph:EmployeeMemberamph:Anp2018EquityIncentivePlanMember2020-09-300001297184amph:EmployeeMemberamph:Anp2018EquityIncentivePlanMember2020-01-012020-09-300001297184amph:EmployeeMemberamph:Anp2018EquityIncentivePlanMember2019-01-012019-12-310001297184amph:EmployeeStockPurchasePlan2014Member2020-09-300001297184amph:The2015EquityIncentivePlanMember2020-09-300001297184amph:The2015EquityIncentivePlanMember2020-01-012020-01-010001297184us-gaap:RestrictedStockUnitsRSUMember2019-12-310001297184amph:PresidentGeneralCounselAndMemberOfBoardOfDirectorsMemberus-gaap:RestrictedStockUnitsRSUMember2020-04-012020-04-300001297184amph:PresidentGeneralCounselAndMemberOfBoardOfDirectorsMemberus-gaap:EmployeeStockOptionMember2020-04-012020-04-300001297184amph:Anp2018EquityIncentivePlanMember2019-06-012019-06-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:PhytonadioneMember2020-07-012020-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:OtherFinishedPharmaceuticalProductsMember2020-07-012020-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:NaloxoneMember2020-07-012020-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:LidocaineMember2020-07-012020-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:EpinephrineMember2020-07-012020-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:EnoxaparinMember2020-07-012020-09-300001297184country:US2020-07-012020-09-300001297184country:FR2020-07-012020-09-300001297184country:CN2020-07-012020-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:PhytonadioneMember2020-01-012020-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:OtherFinishedPharmaceuticalProductsMember2020-01-012020-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:NaloxoneMember2020-01-012020-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:LidocaineMember2020-01-012020-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:EpinephrineMember2020-01-012020-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:EnoxaparinMember2020-01-012020-09-300001297184country:US2020-01-012020-09-300001297184country:FR2020-01-012020-09-300001297184country:CN2020-01-012020-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:PhytonadioneMember2019-07-012019-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:OtherFinishedPharmaceuticalProductsMember2019-07-012019-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:NaloxoneMember2019-07-012019-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:LidocaineMember2019-07-012019-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:EpinephrineMember2019-07-012019-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:EnoxaparinMember2019-07-012019-09-300001297184country:US2019-07-012019-09-300001297184country:FR2019-07-012019-09-300001297184country:CN2019-07-012019-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:PhytonadioneMember2019-01-012019-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:OtherFinishedPharmaceuticalProductsMember2019-01-012019-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:NaloxoneMember2019-01-012019-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:LidocaineMember2019-01-012019-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:EpinephrineMember2019-01-012019-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:EnoxaparinMember2019-01-012019-09-300001297184country:US2019-01-012019-09-300001297184country:FR2019-01-012019-09-300001297184country:CN2019-01-012019-09-300001297184country:US2020-09-300001297184country:FR2020-09-300001297184country:CN2020-09-300001297184country:US2019-12-310001297184country:FR2019-12-310001297184country:CN2019-12-310001297184us-gaap:MachineryAndEquipmentMember2020-09-300001297184us-gaap:LeaseholdImprovementsMember2020-09-300001297184us-gaap:LandMember2020-09-300001297184us-gaap:ConstructionInProgressMember2020-09-300001297184us-gaap:BuildingMember2020-09-300001297184amph:FurnitureFixturesAndVehiclesMember2020-09-300001297184us-gaap:MachineryAndEquipmentMember2019-12-310001297184us-gaap:LeaseholdImprovementsMember2019-12-310001297184us-gaap:LandMember2019-12-310001297184us-gaap:ConstructionInProgressMember2019-12-310001297184us-gaap:BuildingMember2019-12-310001297184amph:FurnitureFixturesAndVehiclesMember2019-12-310001297184amph:AnpMember2018-07-012018-07-310001297184us-gaap:UseRightsMemberamph:CommitmentToDevelopLandMember2020-01-012020-09-300001297184us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300001297184us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-04-012020-06-300001297184us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-310001297184us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-07-012019-09-300001297184us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-04-012019-06-300001297184us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-03-310001297184us-gaap:NoncontrollingInterestMember2019-01-012019-03-310001297184us-gaap:RetainedEarningsMember2020-07-012020-09-300001297184us-gaap:RetainedEarningsMember2020-04-012020-06-300001297184us-gaap:RetainedEarningsMember2020-01-012020-03-310001297184us-gaap:RetainedEarningsMember2019-07-012019-09-300001297184us-gaap:RetainedEarningsMember2019-04-012019-06-300001297184amph:EnoxaparinPatentLitigationMemberus-gaap:PendingLitigationMember2011-09-012011-09-300001297184amph:CommitmentsToPurchaseEquipmentAndRawMaterialsMember2020-01-012020-09-300001297184amph:WorkingCapitalLoanDueJune2021Memberamph:EverbrightBankOfChinaMember2020-09-300001297184amph:MortgagePayableDueOctober2026Memberamph:EastWestBankMember2020-09-300001297184amph:MortgagePayableDueJune2027Memberamph:EastWestBankMember2020-09-300001297184amph:MortgagePayableDueFebruary2021Memberamph:EastWestBankMember2020-09-300001297184amph:MortgagePayableDueAugust2027Memberamph:CathayBankMember2020-09-300001297184amph:LineOfCreditDueAugust2021Memberamph:ChinaMerchantBankMember2020-09-300001297184amph:FrenchGovernmentLoanDueJuly2021Memberamph:SeineNormandieWaterAgencyMember2020-09-300001297184amph:FrenchGovernmentLoan4DueDecember2026Memberamph:SeineNormandieWaterAgencyMember2020-09-300001297184amph:EquipmentLoanDueJune2021Memberamph:EastWestBankMember2020-09-300001297184amph:EquipmentLoanDueFebruary2024Memberamph:EastWestBankMember2020-09-300001297184amph:EquipmentLoanDueDecember2022Memberamph:EastWestBankMember2020-09-300001297184amph:AcquisitionLoanDueJune2024Memberamph:CathayBankMember2020-09-300001297184amph:MortgagePayableDueOctober2026Memberamph:EastWestBankMember2019-12-310001297184amph:MortgagePayableDueJune2027Memberamph:EastWestBankMember2019-12-310001297184amph:MortgagePayableDueFebruary2021Memberamph:EastWestBankMember2019-12-310001297184amph:MortgagePayableDueAugust2027Memberamph:CathayBankMember2019-12-310001297184amph:FrenchGovernmentLoanDueJune2020Memberamph:SeineNormandieWaterAgencyMember2019-12-310001297184amph:FrenchGovernmentLoanDueJuly2021Memberamph:SeineNormandieWaterAgencyMember2019-12-310001297184amph:FrenchGovernmentLoan4DueDecember2026Memberamph:SeineNormandieWaterAgencyMember2019-12-310001297184amph:EquipmentLoanDueJune2021Memberamph:EastWestBankMember2019-12-310001297184amph:EquipmentLoanDueFebruary2024Memberamph:EastWestBankMember2019-12-310001297184amph:EquipmentLoanDueDecember2022Memberamph:EastWestBankMember2019-12-310001297184amph:AcquisitionLoanDueJune2024Memberamph:CathayBankMember2019-12-310001297184amph:NotePayableToMerckMember2019-12-310001297184us-gaap:SettledLitigationMember2019-06-272019-06-270001297184amph:EquipmentLineOfCreditDueSeptember2025Memberamph:EastWestBankMember2020-09-010001297184amph:EquipmentLineOfCreditDueSeptember2025Memberamph:EastWestBankMember2020-09-300001297184us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-09-300001297184us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2020-09-300001297184us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001297184us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001297184amph:AnpMemberamph:CrudeHeparinMember2019-07-012019-09-300001297184amph:AnpMemberamph:CrudeHeparinMember2019-01-012019-09-300001297184us-gaap:TrademarksMember2020-09-300001297184us-gaap:TrademarksMember2019-12-310001297184us-gaap:CorporateBondSecuritiesMember2020-09-300001297184us-gaap:CorporateBondSecuritiesMember2019-12-310001297184amph:FinishedPharmaceuticalProductsSegmentMember2020-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMember2019-12-310001297184amph:InternationalMedicationSystemsUkLimitedMemberamph:AcquiredInternationalProductRightsMember2020-01-012020-09-300001297184us-gaap:UseRightsMember2020-01-012020-09-300001297184us-gaap:PatentsMember2020-01-012020-09-300001297184amph:InternationalMedicationSystemsUkLimitedMemberamph:AcquiredInternationalProductRightsMember2019-01-012019-12-310001297184us-gaap:UseRightsMember2019-01-012019-12-310001297184us-gaap:PatentsMember2019-01-012019-12-310001297184us-gaap:OtherIntangibleAssetsMember2019-01-012019-12-3100012971842019-01-012019-12-310001297184us-gaap:UseRightsMemberamph:CommitmentToInvestMember2012-11-012012-11-300001297184us-gaap:UseRightsMemberamph:CommitmentToInvestMember2010-01-012010-01-310001297184amph:InternationalMedicationSystemsUkLimitedMemberamph:AcquiredInternationalProductRightsMember2020-09-300001297184us-gaap:UseRightsMember2020-09-300001297184us-gaap:PatentsMember2020-09-300001297184amph:InternationalMedicationSystemsUkLimitedMemberamph:AcquiredInternationalProductRightsMember2019-12-310001297184us-gaap:UseRightsMember2019-12-310001297184us-gaap:PatentsMember2019-12-310001297184us-gaap:OtherIntangibleAssetsMember2019-12-310001297184amph:EmployeeConsultantAndDirectorsStockOptionsMember2020-09-300001297184amph:EmployeeConsultantAndDirectorsStockOptionsMember2020-01-012020-09-300001297184amph:EastWestBankMember2020-09-300001297184amph:EastWestBankMember2019-12-310001297184amph:FinishedPharmaceuticalProductsSegmentMember2020-07-012020-09-300001297184amph:ActivePharmaceuticalIngredientSegmentMember2020-07-012020-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMember2020-01-012020-09-300001297184amph:ActivePharmaceuticalIngredientSegmentMember2020-01-012020-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMember2019-07-012019-09-300001297184amph:ActivePharmaceuticalIngredientSegmentMember2019-07-012019-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMember2019-01-012019-09-300001297184amph:ActivePharmaceuticalIngredientSegmentMember2019-01-012019-09-300001297184amph:EquipmentLineOfCreditDueSeptember2025Memberamph:EastWestBankMemberus-gaap:PrimeRateMember2020-09-012020-09-010001297184us-gaap:UseRightsMemberamph:CommitmentToDevelopLandMember2012-11-300001297184amph:McKessonMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-07-012020-09-300001297184amph:CardinalHealthMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-07-012020-09-300001297184amph:AmerisourceBergenMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-07-012020-09-300001297184amph:McKessonMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-09-300001297184amph:McKessonMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-09-300001297184amph:CardinalHealthMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-09-300001297184amph:CardinalHealthMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-09-300001297184amph:AmerisourceBergenMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-09-300001297184amph:AmerisourceBergenMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-09-300001297184amph:McKessonMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2019-07-012019-09-300001297184amph:CardinalHealthMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2019-07-012019-09-300001297184amph:AmerisourceBergenMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2019-07-012019-09-300001297184amph:McKessonMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-12-310001297184amph:CardinalHealthMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-12-310001297184amph:AmerisourceBergenMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-12-310001297184amph:McKessonMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-09-300001297184amph:CardinalHealthMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-09-300001297184amph:AmerisourceBergenMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-09-300001297184us-gaap:TreasuryStockMember2020-09-300001297184us-gaap:CommonStockMember2020-09-300001297184us-gaap:TreasuryStockMember2020-06-300001297184us-gaap:CommonStockMember2020-06-300001297184us-gaap:TreasuryStockMember2020-03-310001297184us-gaap:CommonStockMember2020-03-310001297184us-gaap:TreasuryStockMember2019-12-310001297184us-gaap:CommonStockMember2019-12-310001297184us-gaap:TreasuryStockMember2019-09-300001297184us-gaap:CommonStockMember2019-09-300001297184us-gaap:TreasuryStockMember2019-06-300001297184us-gaap:CommonStockMember2019-06-300001297184us-gaap:TreasuryStockMember2019-03-310001297184us-gaap:CommonStockMember2019-03-310001297184us-gaap:TreasuryStockMember2018-12-310001297184us-gaap:CommonStockMember2018-12-310001297184us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-09-300001297184us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2020-09-300001297184us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001297184us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001297184us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-09-300001297184us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-09-300001297184us-gaap:FairValueMeasurementsRecurringMember2020-09-300001297184us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001297184us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001297184us-gaap:FairValueMeasurementsRecurringMember2019-12-310001297184amph:EmployeeAndNonEmployeeStockOptionsMember2020-01-012020-09-300001297184us-gaap:SellingAndMarketingExpenseMember2020-07-012020-09-300001297184us-gaap:RestrictedStockUnitsRSUMember2020-07-012020-09-300001297184us-gaap:ResearchAndDevelopmentExpenseMember2020-07-012020-09-300001297184us-gaap:GeneralAndAdministrativeExpenseMember2020-07-012020-09-300001297184us-gaap:EmployeeStockOptionMember2020-07-012020-09-300001297184us-gaap:CostOfSalesMember2020-07-012020-09-300001297184amph:EmployeeStockPurchasePlan2014Member2020-07-012020-09-300001297184amph:Anp2018EquityIncentivePlanMember2020-07-012020-09-300001297184amph:PresidentGeneralCounselAndMemberOfBoardOfDirectorsMemberus-gaap:RestrictedStockUnitsRSUMember2020-01-012020-09-300001297184amph:PresidentGeneralCounselAndMemberOfBoardOfDirectorsMemberus-gaap:EmployeeStockOptionMember2020-01-012020-09-300001297184us-gaap:SellingAndMarketingExpenseMember2020-01-012020-09-300001297184us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-09-300001297184us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-09-300001297184us-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-09-300001297184us-gaap:EmployeeStockOptionMember2020-01-012020-09-300001297184us-gaap:CostOfSalesMember2020-01-012020-09-300001297184amph:EmployeeStockPurchasePlan2014Member2020-01-012020-09-300001297184amph:Anp2018EquityIncentivePlanMember2020-01-012020-09-300001297184us-gaap:SellingAndMarketingExpenseMember2019-07-012019-09-300001297184us-gaap:RestrictedStockUnitsRSUMember2019-07-012019-09-300001297184us-gaap:ResearchAndDevelopmentExpenseMember2019-07-012019-09-300001297184us-gaap:GeneralAndAdministrativeExpenseMember2019-07-012019-09-300001297184us-gaap:EmployeeStockOptionMember2019-07-012019-09-300001297184us-gaap:CostOfSalesMember2019-07-012019-09-300001297184amph:EmployeeStockPurchasePlan2014Member2019-07-012019-09-300001297184amph:Anp2018EquityIncentivePlanMember2019-07-012019-09-300001297184us-gaap:SellingAndMarketingExpenseMember2019-01-012019-09-300001297184us-gaap:RestrictedStockUnitsRSUMember2019-01-012019-09-300001297184us-gaap:ResearchAndDevelopmentExpenseMember2019-01-012019-09-300001297184us-gaap:GeneralAndAdministrativeExpenseMember2019-01-012019-09-300001297184us-gaap:EmployeeStockOptionMember2019-01-012019-09-300001297184us-gaap:CostOfSalesMember2019-01-012019-09-300001297184amph:EmployeeStockPurchasePlan2014Member2019-01-012019-09-300001297184amph:Anp2018EquityIncentivePlanMember2019-01-012019-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:PrimatenemistMember2020-07-012020-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:PrimatenemistMember2020-01-012020-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:PrimatenemistMember2019-07-012019-09-300001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:PrimatenemistMember2019-01-012019-09-300001297184us-gaap:NoncontrollingInterestMember2020-04-012020-06-300001297184us-gaap:NoncontrollingInterestMember2020-01-012020-03-310001297184us-gaap:NoncontrollingInterestMember2019-07-012019-09-300001297184us-gaap:NoncontrollingInterestMember2019-04-012019-06-3000012971842020-11-020001297184us-gaap:ParentMember2020-07-012020-09-300001297184us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-300001297184us-gaap:ParentMember2020-04-012020-06-300001297184us-gaap:AdditionalPaidInCapitalMember2020-04-012020-06-3000012971842020-04-012020-06-300001297184us-gaap:ParentMember2020-01-012020-03-310001297184us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-3100012971842020-01-012020-03-310001297184us-gaap:ParentMember2019-07-012019-09-300001297184us-gaap:AdditionalPaidInCapitalMember2019-07-012019-09-3000012971842019-07-012019-09-300001297184us-gaap:ParentMember2019-04-012019-06-300001297184us-gaap:AdditionalPaidInCapitalMember2019-04-012019-06-3000012971842019-04-012019-06-300001297184us-gaap:AdditionalPaidInCapitalMember2019-01-012019-03-310001297184us-gaap:RestrictedStockUnitsRSUMember2020-09-300001297184amph:RestrictedStockUnitsIssuedAsCompensationMember2020-01-012020-09-300001297184us-gaap:AccountsReceivableMember2020-01-012020-09-300001297184us-gaap:AccountsPayableAndAccruedLiabilitiesMember2020-01-012020-09-300001297184us-gaap:AccountsReceivableMember2019-01-012019-12-310001297184us-gaap:AccountsPayableAndAccruedLiabilitiesMember2019-01-012019-12-3100012971842019-09-3000012971842018-12-310001297184us-gaap:CustomerConcentrationRiskMember2020-01-012020-09-300001297184us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-07-012020-09-300001297184us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-09-300001297184us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-09-300001297184us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2019-07-012019-09-300001297184us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-12-310001297184us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-09-300001297184amph:EquipmentLineOfCreditDueSeptember2025Memberamph:EastWestBankMember2020-09-012020-09-0100012971842019-01-012019-09-300001297184amph:AnpMember2018-07-022018-07-020001297184amph:EmployeeStockPurchasePlan2014Member2020-05-012020-05-310001297184us-gaap:RetainedEarningsMember2019-01-012019-03-310001297184us-gaap:ParentMember2019-01-012019-03-3100012971842019-01-012019-03-310001297184amph:EmployeeAndNonEmployeeStockOptionsMember2020-07-012020-09-300001297184amph:EmployeeAndNonEmployeeStockOptionsMember2019-07-012019-09-300001297184amph:EmployeeAndNonEmployeeStockOptionsMember2019-01-012019-09-3000012971842020-01-012020-09-300001297184us-gaap:NoncontrollingInterestMember2020-07-012020-09-3000012971842020-07-012020-09-3000012971842020-09-3000012971842019-12-31iso4217:USDiso4217:USDxbrli:sharesxbrli:pureamph:itemxbrli:sharesamph:segment

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2020

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from             to             

Commission file number 001-36509

AMPHASTAR PHARMACEUTICALS, INC.

(Exact name of Registrant as specified in its charter)

Delaware

 

33-0702205

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer
Identification No.)

11570 6th Street

 

Rancho Cucamonga, CA

 

91730

(Address of principal executive offices)

(zip code)

(909) 980-9484

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes       No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes       No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  

Securities registered pursuant to Section 12(b) of the Act:

T

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

AMPH

The NASDAQ Stock Market LLC

The number of shares outstanding of the registrant’s common stock as of November 2, 2020 was 47,504,019.

Table of Contents

AMPHASTAR PHARMACEUTICALS, INC.

TABLE OF CONTENTS

FORM 10-Q FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2020

Special Note About Forward-Looking Statements

Part I. FINANCIAL INFORMATION

PAGE

Item 1. Financial Statements (unaudited):

Condensed Consolidated Balance Sheets as of September 30, 2020 and December 31, 2019

1

Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2020 and 2019

2

Condensed Consolidated Statements of Comprehensive Income (Loss) for the Three and Nine Months Ended September 30, 2020 and 2019

3

Condensed Consolidated Statements of Stockholders’ Equity for the Three and Nine Months Ended September 30, 2020 and 2019

4

Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2020 and 2019

6

Notes to Condensed Consolidated Financial Statements

7

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

30

Item 3. Quantitative and Qualitative Disclosure about Market Risk

41

Item 4. Controls and Procedures

41

Part II. OTHER INFORMATION

Item 1. Legal Proceedings

42

Item 1A. Risk Factors

42

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

46

Item 3. Defaults Upon Senior Securities

47

Item 4. Mine Safety Disclosures

47

Item 5. Other Information

47

Item 6. Exhibits

47

Signatures

48

Table of Contents

SPECIAL NOTE ABOUT FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q, or Quarterly Report, contains “forward-looking statements” that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by the following words: “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements relate to future events or future financial performance or condition and involve known and unknown risks, uncertainties and other factors that could cause actual results, levels of activity, performance or achievement to differ materially from those expressed or implied by the forward-looking statements. These forward-looking statements include, but are not limited to, statements about:

our expectations regarding the sales and marketing of our products;
our expectations regarding our manufacturing and production and the integrity of our supply chain for our products, including the risks associated with our single source suppliers;
the impact of the COVID-19 pandemic and related responses of business and governments to the pandemic on our operations and personnel, and on commercial activity and demand across our business operations and results of operations;
interruptions to our manufacturing and production as a result of natural catastrophic events or other causes beyond our control such as power disruptions or widespread disease outbreaks, such as the COVID-19 pandemic;
global, national and local economic and market conditions, specifically with respect to geopolitical uncertainty, and the COVID-19 pandemic;
the timing and likelihood of U.S. Food and Drug Administration, or FDA, approvals and regulatory actions on our product candidates, manufacturing activities and product marketing activities;
our ability to advance product candidates in our platforms into successful and completed clinical trials and our subsequent ability to successfully commercialize our product candidates;
our ability to compete in the development and marketing of our products and product candidates;
our expectations regarding the business expansion plans for our Chinese subsidiary, ANP;
the potential for adverse application of environmental, health and safety and other laws and regulations on our operations;
our expectations for market acceptance of our new products and proprietary drug delivery technologies, as well as those of our active pharmaceutical ingredient, or API, customers;
the potential for our marketed products to be withdrawn due to patient adverse events or deaths, or if we fail to secure FDA approval for products subject to the Prescription Drug Wrap-Up program;
our expectations in obtaining insurance coverage and adequate reimbursement for our products from third-party payers;
the amount of price concessions or exclusion of suppliers adversely affecting our business;
our ability to establish and maintain intellectual property protection for our products and our ability to successfully defend our intellectual property in cases of alleged infringement;
the implementation of our business strategies, product development strategies and technology utilization;
the potential for exposure to product liability claims;
future acquisitions, divestitures or investments, including the anticipated benefits of such acquisitions, divestitures or investments;
our ability to expand internationally;
economic and industry trends and trend analysis;
our ability to remain in compliance with laws and regulations that currently apply or become applicable to our business both in the United States and internationally;
the impact of trade tariffs, export or import restrictions, or other trade barriers;
the impact of Patient Protection and Affordable Care Act (as amended) and other legislative and regulatory healthcare reforms in the countries in which we operate including the potential for drug price controls;
the impact of global and domestic tax reforms, including the Tax Cuts and Jobs Act of 2017, or the Tax Act, as amended by the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act;
the timing for completion and the validation of the new construction at our ANP and Amphastar facilities;
the timing and extent of share buybacks; and
our financial performance expectations, including our expectations regarding our backlog, revenue, cost of revenue, gross profit or gross margin, operating expenses, including changes in research and development, sales and marketing and general and administrative expenses, and our ability to achieve and maintain future profitability.

You should read this Quarterly Report and the documents that we reference elsewhere in this Quarterly Report completely and with the understanding that our actual results may differ materially from what we expect as expressed or implied by our forward-looking statements. In light of the significant risks and uncertainties to which our forward-looking statements are subject, you should not place undue reliance on or regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified timeframe, or at all. In particular, the extent of COVID-19’s impact on our business will depend on several factors, including the severity, duration and extent of the pandemic, as well as actions taken by governments, businesses,

Table of Contents

and consumers in response to the pandemic, all of which continue to evolve and remain uncertain at this time. We discuss many of these risks and uncertainties in greater detail in this Quarterly Report and in our Annual Report on Form 10-K for the year ended December 31, 2019, particularly in Item 1A. “Risk Factors.” These forward-looking statements represent our estimates and assumptions only as of the date of this Quarterly Report regardless of the time of delivery of this Quarterly Report, and such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this Quarterly Report.

Unless expressly indicated or the context requires otherwise, references in this Quarterly Report to “Amphastar,” “the Company,” “we,” “our,” and “us” refer to Amphastar Pharmaceuticals, Inc. and our subsidiaries.

Table of Contents

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

AMPHASTAR PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share data)

    

September 30, 

    

December 31, 

 

2020

2019

 

(unaudited)

ASSETS

Current assets:

Cash and cash equivalents

$

87,910

$

73,685

Restricted cash

1,865

1,865

Short-term investments

10,873

11,675

Restricted short-term investments

 

2,200

 

2,290

Accounts receivable, net

 

52,382

 

45,376

Inventories

 

108,870

 

110,501

Income tax refunds and deposits

 

1,455

 

311

Prepaid expenses and other assets

 

10,986

 

9,538

Total current assets

 

276,541

 

255,241

Property, plant, and equipment, net

 

245,881

 

233,856

Finance lease right-of-use assets

693

887

Operating lease right-of-use assets

20,256

18,805

Goodwill and intangible assets, net

 

40,377

 

41,153

Other assets

 

7,735

 

11,156

Deferred tax assets

 

22,235

 

25,873

Total assets

$

613,718

$

586,971

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable and accrued liabilities

$

79,292

$

77,051

Income taxes payable

 

1,619

 

2,042

Current portion of long-term debt

 

12,167

 

7,741

Current portion of operating lease liabilities

3,639

3,175

Total current liabilities

 

96,717

 

90,009

Long-term reserve for income tax liabilities

 

3,425

 

3,425

Long-term debt, net of current portion

 

32,903

 

39,394

Long-term operating lease liabilities, net of current portion

17,534

16,315

Deferred tax liabilities

 

823

 

867

Other long-term liabilities

 

11,354

 

9,433

Total liabilities

 

162,756

 

159,443

Commitments and contingencies

Stockholders’ equity:

Preferred stock: par value $0.0001; 20,000,000 shares authorized; no shares issued and outstanding

 

 

Common stock: par value $0.0001; 300,000,000 shares authorized; 54,623,837 and 47,534,215 shares issued and outstanding as of September 30, 2020 and 52,495,483 and 46,576,968 shares issued and outstanding as of December 31, 2019, respectively

 

5

 

5

Additional paid-in capital

 

404,084

 

367,305

Retained earnings

 

124,046

 

116,370

Accumulated other comprehensive loss

 

(4,478)

 

(4,687)

Treasury stock

 

(118,425)

 

(97,627)

Total Amphastar Pharmaceuticals, Inc. stockholders’ equity

 

405,232

 

381,366

Non-controlling interests

45,730

46,162

Total equity

450,962

427,528

Total liabilities and stockholders’ equity

$

613,718

$

586,971

See Accompanying Notes to Condensed Consolidated Financial Statements.

-1-

Table of Contents

AMPHASTAR PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited; in thousands, except per share data)

Three Months Ended

Nine Months Ended

 

September 30, 

September 30, 

    

2020

    

2019

    

2020

    

2019

 

Net revenues

$

83,431

$

80,137

$

253,925

$

238,974

Cost of revenues

 

46,923

 

44,885

 

147,417

 

140,432

Gross profit

 

36,508

 

35,252

 

106,508

 

98,542

Operating expenses:

Selling, distribution, and marketing

 

3,673

 

3,221

 

10,993

9,354

General and administrative

 

11,674

 

11,021

 

38,344

39,774

Research and development

 

17,644

 

18,606

 

49,096

49,209

Total operating expenses

 

32,991

 

32,848

 

98,433

 

98,337

Income from operations

 

3,517

 

2,404

 

8,075

 

205

Non-operating income (expenses):

Interest income

 

161

 

450

 

512

741

Interest expense

 

(175)

 

(22)

 

(286)

(76)

Other income (expenses), net

 

3,575

 

(1,250)

 

3,078

58,172

Total non-operating income (expenses), net

 

3,561

 

(822)

 

3,304

 

58,837

Income before income taxes

 

7,078

 

1,582

 

11,379

 

59,042

Income tax provision

 

2,285

 

598

 

4,490

13,292

Net income

$

4,793

$

984

$

6,889

$

45,750

Net income (loss) attributable to non-controlling interests

$

874

$

(326)

$

(787)

$

(4,215)

Net income attributable to Amphastar Pharmaceuticals, Inc.

$

3,919

$

1,310

$

7,676

$

49,965

Net income per share attributable to Amphastar Pharmaceuticals, Inc. stockholders:

Basic

$

0.08

$

0.03

$

0.16

$

1.06

Diluted

$

0.08

$

0.03

$

0.16

$

1.00

Weighted-average shares used to compute net income per share attributable to Amphastar Pharmaceuticals, Inc. stockholders:

Basic

 

47,496

 

47,239

 

46,886

 

47,030

Diluted

 

49,848

 

50,075

 

48,922

 

50,128

See Accompanying Notes to Condensed Consolidated Financial Statements.

-2-

Table of Contents

AMPHASTAR PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(Unaudited; in thousands)

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

    

2020

    

2019

    

2020

    

2019

 

Net income attributable to Amphastar Pharmaceuticals, Inc.

$

3,919

$

1,310

$

7,676

$

49,965

Other comprehensive income (loss) attributable to Amphastar Pharmaceuticals, Inc., net of income taxes

Foreign currency translation adjustment

 

695

 

(1,625)

 

209

 

(1,835)

Total other comprehensive income (loss) attributable to Amphastar Pharmaceuticals, Inc.

 

695

 

(1,625)

 

209

 

(1,835)

Total comprehensive income (loss) attributable to Amphastar Pharmaceuticals, Inc.

$

4,614

$

(315)

$

7,885

$

48,130

See Accompanying Notes to Condensed Consolidated Financial Statements.

-3-

Table of Contents

AMPHASTAR PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited; in thousands, except share data)

Common Stock

Accumulated

Treasury Stock

Total

Additional

Other

Amphastar

Non-

Paid-in

Retained

Comprehensive

Stockholders'

controlling

Shares

Amount

Capital

Earnings

loss

Shares

Amount

Equity

Interest

Total

Balance as of December 31, 2019

 

52,495,483

$

5

$

367,305

$

116,370

$

(4,687)

 

(5,918,515)

$

(97,627)

$

381,366

$

46,162

$

427,528

Net income attributable to Amphastar Pharmaceuticals, Inc.

 

 

 

 

3,949

 

 

 

 

3,949

 

 

3,949

Other comprehensive loss attributable to Amphastar Pharmaceuticals, Inc.

 

 

 

 

 

(774)

 

 

 

(774)

 

 

(774)

Net loss attributable to non-controlling interest

(424)

(424)

Purchase of treasury stock

 

 

 

 

 

 

(647,246)

(10,950)

(10,950)

 

(10,950)

Issuance of treasury stock in connection with the Company's equity plans

(84)

6,873

84

Issuance of common stock in connection with the Company's equity plans

 

369,508

 

 

(1,238)

 

 

 

 

 

(1,238)

 

 

(1,238)

Share-based compensation expense

 

 

 

5,161

 

 

 

 

 

5,161

 

121

 

5,282

Balance as of March 31, 2020

 

52,864,991

$

5

$

371,144

$

120,319

$

(5,461)

 

(6,558,888)

$

(108,493)

$

377,514

$

45,859

$

423,373

Net loss attributable to Amphastar Pharmaceuticals, Inc.

 

 

 

 

(192)

 

 

 

 

(192)

 

 

(192)

Other comprehensive income attributable to Amphastar Pharmaceuticals, Inc.

 

 

 

 

 

288

 

 

 

288

 

 

288

Net loss attributable to non-controlling interest

(1,237)

(1,237)

Purchase of treasury stock

 

 

 

 

 

 

(329,391)

(5,756)

(5,756)

 

(5,756)

Issuance of treasury stock in connection with the Company's equity plans

 

 

(130)

 

 

 

10,913

130

 

Issuance of common stock in connection with the Company's equity plans

 

1,507,284

 

 

19,448

 

 

 

 

 

19,448

 

 

19,448

Share-based compensation expense

 

 

 

6,379

 

 

 

 

 

6,379

 

134

 

6,513

Balance as of June 30, 2020

 

54,372,275

$

5

396,841

$

120,127

$

(5,173)

 

(6,877,366)

$

(114,119)

$

397,681

$

44,756

$

442,437

Net income attributable to Amphastar Pharmaceuticals, Inc.

 

 

 

 

3,919

 

 

 

 

3,919

 

 

3,919

Other comprehensive income attributable to Amphastar Pharmaceuticals, Inc.

 

 

 

 

 

695

 

 

 

695

 

 

695

Acquisition of additional ownership interest in ANP

(106)

(106)

Net income attributable to non-controlling interest

874

874

Purchase of treasury stock

 

 

 

 

 

 

(214,256)

(4,329)

(4,329)

 

(4,329)

Issuance of treasury stock in connection with the Company's equity plans

 

 

(23)

 

 

 

2,000

23

 

Issuance of common stock in connection with the Company's equity plans

 

251,562

 

 

3,102

 

 

 

 

 

3,102

 

 

3,102

Share-based compensation expense

 

 

 

4,164

 

 

 

 

 

4,164

 

206

 

4,370

Balance as of September 30, 2020

 

54,623,837

$

5

$

404,084

$

124,046

$

(4,478)

 

(7,089,622)

$

(118,425)

$

405,232

$

45,730

$

450,962

-4-

Table of Contents

AMPHASTAR PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited; in thousands, except share data)

<

Common Stock

Accumulated

Treasury Stock

Total

Additional

Other

Amphastar

Non-

Paid-in

Retained

Comprehensive

Stockholders'

controlling

Shares

Amount

Capital

Earnings

loss

Shares

Amount

Equity

Interest

Total

Balance as of December 31, 2018

 

51,438,675

$

5

$

344,434

$

67,485

$

(4,013)

 

(4,807,557)

$

(75,476)

$

332,435

$

31,924

$

364,359

Beginning balance adjustment as a result of the adoption of new accounting standards

(54)

(54)

(54)

Net income attributable to Amphastar Pharmaceuticals, Inc.

 

 

 

 

868

 

 

 

 

868

 

 

868

Other comprehensive loss attributable to Amphastar Pharmaceuticals, Inc.

 

 

 

 

 

(113)

 

 

 

(113)

 

 

(113)

Proceeds from the private placement of ANP

2,588

2,588

16,378

18,966

Net loss attributable to non-controlling interest

(3,022)

(3,022)

Purchase of treasury stock

 

 

 

 

 

 

(145,479)

(3,015)

(3,015)

 

(3,015)

Issuance of treasury stock in connection with the Company's equity plans

(98)

8,334

98

Issuance of common stock in connection with the Company's equity plans

 

604,651

 

 

(2,397)

 

 

 

 

 

(2,397)

 

 

(2,397)

Share-based compensation expense

 

 

 

4,674

 

 

 

 

 

4,674

 

 

4,674

Balance as of March 31, 2019

 

52,043,326

$

5

$

349,201

$

68,299

$

(4,126)

 

(4,944,702)

$

(78,393)

$

334,986

$

45,280

$

380,266

Net income attributable to Amphastar Pharmaceuticals, Inc.

 

 

 

 

47,787